1st Symposium of ThéGéVec Group

As part of the annual meetings of the Coordinated Action on Host-Virus Interactions: Basic and Translational HIV Research (CA41), the ThéGéVec Group is hosting its first symposium on November 28th 2025: "Shaping the Future of Gene Therapy with New Vectors".

28 November 2025

Main points

  • The symposium will take place on November 28th, 2025 at the Institut Pasteur, Paris.
  • Registration is open until November 21st, 2025.

Shaping the Future of Gene Therapy with New Vectors

The ThéGéVec working group, affiliated with Coordinated Action on Host-Virus Interactions: Basic and Translational HIV Research (CA41), is excited to announce its first symposium: “Shaping the Future of Gene Therapy with New Vectors”, marking a key milestone for this newly established working group focused on advancing research in vectorology and gene therapy.

This event will be held in person on 28th November, 2025 at Institut Pasteur.

The symposium will bring together leading experts and researchers to discuss the latest innovations in viral and non-viral vectors technologies and their therapeutic applications. Special emphasis will be placed on fostering collaboration within the scientific community and exploring new strategies for accelerating progress in the field. Research from all areas of vectorology and gene therapy is welcomed for presentation.

Registration is now open and closes on November 21st. The symposium is free to attend, but registration is mandatory (in-person event only).

Abstract submission is now open until September 15th.

Registration Abstract submission

Scientific and organising committee

  • ThéGéVec Coordination Team: Matteo Negroni, Alexis Duvergé, Jean-Christophe Pages, Yves Gaudin, Aurélie Albertini, Anne Galy, Chantal Pichon
  • AC41 Office: Michaela Muller-Trutwin, Victor Appay, Stéphane Emiliani, Anne-Sophie Beignon, Fernando Real, Philippe Benaroch
  • ANRS MIE: Dahlia Chebbah, Guia Carrara, Rana Lebdy, Fabrice Porcheray, Nathalie Alazard (Institut Pasteur)